The glycine receptor (GlyR) Cl -channel belongs to the cysteine-loop family of ligand-gated ion channel receptors. It is best known for mediating inhibitory neurotransmission in motor and sensory reflex circuits of the spinal cord, although glycinergic synapses are also present in the brain stem, cerebellum and retina. Extrasynaptic GlyRs are widely distributed throughout the central nervous system and they are also found in sperm and macrophages. A total of 5 GlyR subunits ( 1-4 and ) have been identified. Embryonic receptors comprise 2 homomers whereas adult receptors comprise predominantly 1 heteromers in a 2:3 stoichiometry. Notably, the 3 subunit is present in synaptic GlyRs that mediate inhibitory neurotransmission onto spinal nociceptive neurons. These receptors are specifically inhibited by inflammatory mediators, implying a role for 3-containing GlyRs in inflammatory pain sensitisation.
INTRODUCTION
Fast synaptic transmission in the central nervous system is mediated by a structurally-and functionally-related group of ion channels termed the cysteine-loop (cys-loop) family, of which the nAChR was the first and is the most intensively studied member [1] . A range of other ion channels also belong to this family, including the anion-permeable GlyR and GABA type-A and type-C receptors (GABA A Rs) and the cation-permeable serotonin type-3 receptor (5-HT 3 R). Together with the GABA A R, the GlyR is responsible for mediating fast inhibitory neurotransmission in the mature central nervous system.
Glycine was originally proposed as a neurotransmitter based on an analysis of its distribution in the spinal cord [2] . It was soon discovered to activate a Cl -conductance in spinal cord motor neurons that was potently and specifically antagonized by the convulsive plant alkaloid, strychnine [3] [4] . Glycine was also shown to be released from spinal neurons upon electrical stimulation [5] and to be accumulated in presynaptic terminals via a high-affinity uptake mechanism [6] . These actions firmly established the status of glycine as a neurotransmitter.
The GlyR was first purified from rat spinal cord in 1982 via strychnine affinity chromatography [7] . This analysis identified three GlyR-associated polypeptides with molecular masses of 48, 58 and 98 kDa, respectively. The 48 and 58 kDa peptides were later shown to correspond to the and subunits, respectively [8] [9] . These subunits share a 47% amino acid sequence homology. The 98 kDa peptide was subsequently identified as the cytoplasmic anchoring protein, gephyrin [10, 11] . Tritiated strychnine was also found to be incorporated irreversibly and specifically into the 48 kD polypeptide upon UV-illumination [7] . Cloning of the strychninebinding 1 subunit was completed in 1987 [8] and its similarity to the already characterised nAChR led to its inclusion into the newly classified cys-loop superfamily. As discussed below, much of our current understanding of GlyR structure and function has been inferred from the vast amount of biochemical and electrophysiological information gained over many years from the nAChR. The aim of this review is to discuss recent advances in the molecular *Address correspondence to this author at the School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia; Tel: +617 3365 3157; Fax: +617 3365 1766; E-mail: j.lynch@uq.edu.au pharmacology of the GlyR. It will also briefly consider the structure of the GlyR, its distribution and role in normal and pathological conditions and its potential as a therapeutic target.
MOLECULAR STRUCTURE AND ACTIVATION MECH-ANISM
Cys-loop receptors comprise an assembly of 5 homologous membrane-spanning subunits arranged symmetrically around a central pore (Fig. 1) . The GlyR can be formed either as an subunit homomer or as a heteromer of and subunits [12] [13] . It (3 and 4) , individual subunits were modelled on the structure of the subunit of Torpedo nAChR [19] using the Homology module of InsightII. Five identical copies of the GlyR 1 subunits generated by this procedure were superimposed over the five subunits of the nAChR.
is generally accepted that each subunit is composed of a large (~210 amino acid) extracellular (EC) ligand-binding domain and 4 transmembrane (TM) -helices, termed M1-M4. However, residues comprising transmembrane helices M2 and M3 have also been proposed to adopt a more extended conformation on the basis of coupled proteolytic and mass spectroscopic analysis [14] . The molecular structure of the EC domain is comparatively well defined since publication of the crystallographic structure of acetylcholine binding protein (AChBP) from the freshwater snail, Lymnaea stagnalis [15] . AChBP shares a 20 -24 % amino acid sequence homology with nAChR subunits, and a 17 % homology with the GlyR 1 subunit (Fig. 2) . This structure shows that each EC domain contains an -helix near its amino terminal followed by a series of 10 -strands. The -strands form a twisted sandwich structure with two hydrophobic cores and ligand binding pockets present at the subunit interfaces. AChBP incorporates the conserved disulfide-bonded loop that is a unique feature of cys-loop receptors. GlyR subunits also contain a second cysteine loop that incorporates a principal glycine binding domain [16] . The conserved cys-loop and the loop connecting -strands 2 and 3 (i.e., loop 2) protrude from the bottom of the structure towards the TM domains and are thus well positioned to transmit ligand binding information from the agonist binding pocket to the channel activation gate in the pore. In other words, these domains are likely to mediate the gating of the receptor.
Perhaps the most important insight provided by AChBP is the structure of the agonist binding pocket. It was already known that agonists bound to sites at the interfaces between adjacent subunits [17] . Indeed, the domains that contributed to the lining of this ligand binding pocket on both sides of the interface had already been comprehensively mapped. However, the 3-dimensional spatial arrangement of these domains was completely unknown. The structure confirmed that the pockets were formed by the subunit interfaces, and showed that they were located approximately midway between the top and bottom of the EC domain (Fig. 3) . The pocket is lined by 3 loops (labelled A, B and C) from one subunit that form the 'principal' (or +) side of the ligand binding pocket, whereas 3 loops (labelled D, E and F) from the adjacent subunit form the 'complementary' (or -) side of the pocket. Viewed from the top of the complex towards the membrane, the complementary side of each AChBP binding site is situated anticlockwise relative to the principal side. The AChBP agonist binding site opens to the outside of the complex.
The elucidation of an atomic model of the Torpedo nAChR TM domains by cryo-electron microscopy confirmed the long-held notion that the TM domains form a bundle of 4 -helices [18] . This model has recently been refined to provide a 4 Å resolution structure of both the TM and EC domains as well as a low resolution structure of the intracellular domain [19] . In agreement with an abundance of functional data (reviewed in [20] ), this model confirms that each subunit contributes an amphipathic M2 domain to the lining of the central pore with the 3 remaining TM domains providing the interface with the lipid bilayer (Fig. 4) . To facilitate comparison between different cys-loop receptor members, a common M2 numbering system is used. This system assigns 1' to the residue at the cytoplasmic membrane surface of the lipid bilayer. With this as the reference point, the residue at the 19' position lies at the external membrane surface. The Torpedo nAChR structure confirmed the membrane surface locations of the 1' and 19' residues and showed that the M2 domain -helical structure extends for about 2.5 -helical turns beyond the extracellular membrane border to terminate at residue 28'. The Torpedo structure [18] also showed the M2 domains to be kinked radially inwards to form a central constriction at the membrane midpoint, in the region 9' -13' (Fig.  4) . Residues at the apex of the kink were proposed to form hydrophobic bonds with their counterparts on neighbouring M2 domains [18] . These bonds appear to balance the M2 domains into a 5-fold radially symmetrical arrangement that holds the channel closed.
This model predicts that the channel would open spontaneously if the midpoint hydrophobic bonds were broken. However, the existence of a midpore hydrophobic girdle in the homopentameric nicotinic 7-5HT 3A chimera has been challenged on the grounds that zinc (presumably in its hydrated state) efficiently traverses the pore midpoint region in the closed state, and that receptors incorporating a ring of polar residues at both the 9' and 13' positions did not gate spontaneously [21] .
The location of the activation gate is the subject of on-going debate. The Torpedo nAChR structure suggests the gate is formed by the central hydrophobic girdle [18] whereas several other lines of evidence suggest that it may be formed by the pore selectivity region in the -2' to 2' region [22] [23] , [21] . It does not seem possible at this point to reconcile all available data into a single unified model. The complexities of the GlyR ionic permeation and selectivity mechanisms have recently been comprehensively reviewed [24] .
The M3 and M4 domains are linked by a long intracellular domain that contains phosphorylation sites and other contact sites for cytoplasmic factors such as gephyrin and ubiquitin [25] [26] . This region is poorly conserved in both length and amino acid composition among cys-loop receptor members and thus may show substantial structural variation between subunits.
AChBP crystal structures have now been resolved in complexes with ligands such as HEPES buffer [15] , the agonists, nicotine and carbamylcholine [27] and the peptide antagonists, -cobratoxin and -conotoxin [28] [29] . From a comparison of these structures, it seems that only binding domain loops C and F undergo substantial conformational changes in the presence of different ligands. However, it is important to note that these structural changes were seen in the absence of the TM domains. The extent to which the observed structural changes are modified by the presence of the TM domains is not yet known.
As discussed above, the refined structure of the Torpedo nAChR provides a high resolution model of both the EC and TM domains in a closed state [19] . The same group had previously interpreted low-resolution electron diffraction images of Torpedo nAChRs obtained in both the closed and open states using the AChBP crystal structure as a template [30] . In modelling the structural changes, they divided the subunit into inner and outer sheets (as defined above) and considered each separately. Upon agonist binding, the outer sheets were found to undergo an upwards tilt around an axis parallel with the membrane plane. Simultaneously, the inner part rotated ~15 o in a clockwise direction (when viewed from above) around an axis perpendicular to the membrane plane. The rotation of the inner sheets was viewed as the crucial event in transmitting agonist-binding information to the channel gate [30] . The inner sheets contain 2 loops: the conserved cysteine loop (i.e., the cys-loop) and the loop linking 1 and 2 (i.e., loop 2). Both Fig. (3) . Model of GlyR 1 dimer. The left panel shows the agonist binding interface (viewed along the plane of the membrane towards the receptor from the outside) and includes glycine binding residues situated on the -face (F63, R65) and the + face (F151, Y194, T196, F199) of adjacent subunits. Space-filled representations of the atoms of these sidechains are rendered in CPK. No attempt was made to optimise the sidechain configurations required for binding of agonist. The right panel displays the inhibitory zinc binding site (viewed along plane of the membrane from inside the pentameric complex) also includes residues situated on the -face (H109, T133) and the + face (H107) of adjacent subunits. Space-filled representations of the atoms of these important sidechains are rendered in CPK. Again, no attempt was made to model optimal sidechain configurations required for binding of zinc. The ribbon representation of individual subunits was coloured grey for random coil, red for -helices and yellow for -sheets.
loops are ideally located to interact directly with the M2-M3 loop at the top of the TM -helical bundle [30] .
The upwards tilting movement of the outer sheets (referred to above) also has the effect of clasping loop C tightly around the bound agonist [30] . This movement is likely to be propagated directly to the TM domains by a rigid body movement of 10, which at one end forms an arm of loop C and at the other end links onto the end of the M1 -helix. Thus, the region of contact between 10 and the M1 domain (referred to hereafter as the 'pre-M1 domain') probably also moves with channel gating.
Many groups have attempted to probe the molecular interactions between the EC and TM domains. Unwin's [18] suggestion that a loop 2 hydrophobic residue inserts into the end of the M2 helix like a 'pin in a socket' is now not widely accepted [31] [32] . However, his proposal that pre-M1 domain and loop 2 move closer together in the open state is compatible with results obtained using other techniques [33, 34] . It is now evident that ligand binding induces breaks and rearrangements in ionic and hydrophobic bonds linking a triad of domains comprising the pre-M1 domain, loop 2 and the M2-M3 loop. A recent elegant study identifies what are probably the major rearrangements in this process [34] . It is likely that this linkage mechanism is conserved to a large extent among cys-loop receptors because chimeras comprised of the EC domain of one family member and the TM domain of another member have been shown to produce agonist-gated channels. For example, the glycine 1 EC domain fused to the nicotinic 7 TM domain produces a glycine-gated channel [35] and the GABA C 1 EC domain coupled to the GlyR 1 TM domain produces a GABA-gated channel [36] . The end effect is that these conformational rearrangements alter the structure of the M2-M3 loop, and this in turn prises the M2 towards the open conformation. It is not known whether the cooperative activation of all subunits is required for this final step. Because partial and full agonists induce similar conformational changes in the GlyR M2-M3 domain [37] , it is likely that differences in agonist efficacy result from a differential ability to stabilise a common activated conformation. As discussed below, the antagonist picrotoxin has recently been shown to promote a conformational state in M2-M3 domain that cannot be induced by glycine [38] . This suggests that the GlyR M2-M3 domain may act to integrate information from a variety of different ligand binding sites and send a net signal to the activation gate.
Based on differences in the electron density images of the nAChR in the closed and open states, Unwin [39] originally proposed that channel opening was caused by a rotation of the M2 domains around their long axes. This model has also been supported by a functional data from the GABA A R receptor [40] which showed that pore-lining cysteines at corresponding positions in adjacent subunits could crosslink with each other in the open state only. These results were explained by proposing that channel opening was caused by a contra-rotation of the two adjacent subunits. However, a recent detailed study by Cymes and Grosman [22] , which measured the reaction rates of protons with histidine sidechains substituted one-at-a-time for every M2 residue, found that the relative orientation of each residue with respect to the pore lumen did not change significantly as the channel opened and closed. Another recent study concluded that channel opening was mediated by a rigid tilting motion of the five M2 domains resulting in an increased diameter at the intracellular end of the pore [21] . Both studies argue against an M2 domain rotation model. Thus, there is as yet no universally accepted model of the cys-loop receptor channel opening mechanism.
DIVERSITY AND DISTRIBUTION OF SUBUNITS
A total of 4 subunits ( 1 -4) and one subunit have so far been identified. Amino acid sequence alignments of 1, 3 and subunits are displayed in (Fig. 2) . As noted above, all subunits can form functional homomeric receptors, although the subunit is functionally expressed only as a heteromer with the subunit. In the rat, distribution of both 1 and subunit mRNA are low prenatally, but increase rapidly from birth to reach a maximum by the end of the third postnatal week [41] [42] . The developmental expression pattern of the 3 subunit parallels that of the 1 except that it is expressed at very low levels outside the dorsal horn. The subunit shows a more general distribution throughout the spinal cord and the brain with its distribution in the lower brainstem corresponding to that of the 1 subunit [43] . In contrast, the 2 subunit mRNA is present at high levels prenatally but undergoes a rapid decline postnatally, although it is present at very low levels in the adult [41] [42] . The 4 subunit has been identified in present in the mouse [44] , chick [45] and zebrafish [46] cDNA libraries. In humans, however, GLRA4 is a pseudogene [47] .
The above expression patterns imply that the 2 subunit predominates in neonates and the 1 and subunits predominate in adult rats [48] . Several studies have shown that the switch from 2 to 1 is incomplete and that 2 subunit expression persists into adulthood in the retina [49] and auditory brainstem [50] . Embryonic homomeric 2 GlyRs are believed to be involved in cell-to-cell communication, neuronal differentiation and synaptogenesis rather than synaptic transmission. This is because gephyrin, which is required for anchoring the GlyR at the postsynaptic membrane, binds only to the subunit and, therefore, 2 homomers have no means of clustering at synapses. Homomeric 2 GlyRs are also considered to open too slowly to effectively mediate synaptic transmission [52] . Glycinergic synaptic transmission in the embryonic and neonatal rat is likely to be mediated by heteromeric 2 and 1 receptors respectively [53] [54] .
DISTRIBUTION AND PHYSIOLOGICAL ROLE
Upon binding of glycine to GlyR, the channel pore opens rapidly allowing Cl -ions to diffuse across the membrane. However, the direction of the flux depends on the electrochemical gradient for Cl -. In neurons, KCC2, a potassium-chloride cotransporter, and NKCC1, a sodium-potassium-chloride cotransporter, together play a key role in modulating glycine-mediated currents through regulation of intracellular chloride concentrations [55] [56] . While KCC2 normally reduces the concentration of intracellular chloride ions, NKCC1 exerts the opposite effect. In embryonic neurons, KCC2 expression levels are low and NKCC1 expression levels are high. Hence, embryonic neurons have a high intracellular Cl -concentration and activation induces an outward Cl -flux that may result in a supra-threshold depolarization. It should be noted, however, that the subthreshold depolarization may be inhibitory if it is accompanied by a conductance increase that shunts excitatory cationic currents. At later stages in development, NKCC1 expression levels decrease while KCC2 expression levels increase. As a consequence, a much lower intracellular Cl -concentration is maintained in adult neurons (3 -5 mM). Since the Cl -equilibrium potential is now more negative than the cell resting potential, channel opening induces an inward Cl -flux that inhibits neuronal firing. Thus, Cl -fluxes are generally excitatory in embryonic neurons and inhibitory in adult neurons.
GlyRs are best known for mediating inhibitory synaptic transmission in motor reflex circuits of the spinal cord. A dramatic illustration of the physiological role of these circuits can be gleaned from the behavioral deficits that accompany the rare human hereditary disorder, hyperekplexia or startle disease. This disorder is characterized by an exaggerated reflex response to unexpected stimuli. Classically, this response may take the form of a complete but temporary loss of muscular rigidity, resulting in an unprotected fall, with consciousness remaining unaffected throughout. The disease phenotype is similar to that produced by sub-lethal strychnine poisoning. Startle disease is caused by mutations that disrupt the efficient functioning of glycinergic synapses. Most startle disease mutations result in missense mutations to the 1 subunit, which in turn results in impairment of the surface expression, glycine sensitivity or single channel conductance of 1 subunit-containing GlyRs [20] .
Startle disease symptoms can also result from mutations that affect other proteins involved in the development, maintenance or function of glycinergic synapses. For example, an hereditary mutation to human gephyrin results in a hyperekplexia phenotype [57] , and targeted deletion of the glycine transporter subtype 2 gene produces a startle phenotype in mice [58] . The causal relationship between GlyR mutations and startle disease demonstrates that glycinergic spinal interneurons are responsible for ensuring that skeletal muscle motor neurons receive the appropriate degree of excitation for particular tasks. Interestingly, the symptoms of startle disease are effectively treated by benzodiazepines, with clonazepam the current drug of choice [59] . Because clonazepam increases current through GABA A Rs but not GlyRs, its clinical efficacy implies that defective GlyRs at spinal synapses may be partially replaced by GABA A Rs. Evidence of enhanced GABAergic inhibition in a mouse model of startle disease is consistent with this hypothesis [60] . It should also be noted that in some regions of the CNS, glycine and GABA can be released from the same presynaptic terminal [61] .
GlyRs also mediate inhibitory neurotransmission in the superficial layers (I and II) of the spinal cord dorsal horn, where nociceptive afferents terminate [62] [63] [64] . Prostaglandin E2 (PGE 2 ) was found to specifically reduce the glycinergic synaptic current in lamina II neurons via a mechanism involving the activation of the EP2 receptor and protein kinase A (PKA)-dependent phosphorylation [64] . A subsequent immuno-labelling study showed that the 3 GlyR subunit is highly expressed at synapses in laminae I and II of the dorsal horn [65] . Furthermore, currents in recombinantly expressed 3 GlyRs were selectively inhibited following PKAdependent phosphorylation [65] . It was thus hypothesised that dorsal horn 3 subunits were selectively inhibited by inflammatory pain mediators. A GlyR 3 knockout mouse was generated to test this theory. Although GlyR 3 -/-mice displayed no overt behavioural phenotype, the PGE 2 -dependent decrease of lamina II glycinergic currents seen in normal mice was abolished [65] . Behaviourally, normal and knockout mice responded similarly to non-painful tactile stimuli and acute pain stimuli. However, peripheral inflammation produced pain sensitisation in normal animals but not in the GlyR 3 -/-animals [65] . Satisfyingly, EP 2 -/-mice exhibited an identical phenotype [66] . Together, these results show that the currents carried by 3-containing GlyRs are selectively inhibited during inflammation. This inhibition would reduce the inhibitory drive onto nociceptive projection neurons, thereby increasing the transmission of nociceptive stimuli to the brain. This mechanism could explain why inflammation often leads to exaggerated pain sensation as a result of an increase in responsiveness of peripheral nociceptors (hyperalgesia) or by conversion of non-painful into painful stimuli (allodynia). These findings have established the 3 subunit as a potential molecular target in the search for new pain therapies [67, 68] . Although it should be possible to compensate for the effects of inflammation on 3-containing GlyRs by increasing the current through synaptic 1-containing GlyRs, the risk of sideeffects is higher given that 1 subunits are more widespread outside the dorsal horn. Unfortunately, however, almost nothing is known about the molecular pharmacological properties of 3-containing GlyRs.
Synaptic GlyRs are also present in the retina, where they are involved in the switch from day to night vision [69] . A recent study has also demonstrated a crucial role for 2 GlyRs in rod photoreceptor development [70] . Glycinergic synapses also are found in several brainstem nuclei, particularly those of the central auditory pathways [20] , where they are important for directional hearing [71] . Extrasynaptic GlyRs are widely distributed throughout the adult nervous system, having so far been found in the cortex [72] , hippocampus [73] and basolateral amygdala [74] , among other areas. Although there has been little systematic investigation into their roles, these extrasynaptic GlyRs have been postulated to mediate tonic inhibition [73] . In support of such a role, a recent report demonstrated that 3 subunit transcripts can undergo RNA editing resulting in a P185L substitution in the EC domain [75] . This mutation dramatically increases glycine sensitivity with the result that extrasynaptic 3-containing GlyRs in the superior colliculus are held open by ambient glycine, leading to strong tonic inhibition [75] . Interestingly, no obvious morphological or molecular differences were observed in mice incorporating a targeted deletion of the GlyR 2 subunit, and the mice display a complete absence of non-synaptic glycine-gated currents in the cortex [76] .
Finally, GlyR expression is not restricted to neurons. GlyRs are found in sperm, where they contribute to the acrosome reaction that fuses the sperm to the egg [77] . They have also been identified in macrophages and leucocytes where they are thought to mediate the anti-inflammatory effects of glycine [78] .
Although GlyRs are not targeted by therapeutic interventions, they are emerging as promising targets for muscle relaxant and peripheral analgesic drugs. Their physiological roles also imply a potential relevance to inflammation and infertility. Substances would need to be able to enhance (or potentiate) GlyR Cl -flux to be therapeutically useful for any of these disorders. For this reason, this review focuses primarily on the pharmacology of GlyR potentiating agents.
PHYSIOLOGICAL MODULATORS Agonists Amino Acid Agonists
Amino acid agonists activate the GlyR with the following rank order of potency: glycine > -alanine > taurine with a host of others, including GABA, active at much lower potencies [79] . Glycine has the highest affinity and efficacy of all known agonists at recombinantly expressed 1 GlyRs [80] . Single channel kinetic analysis indicates that a minimum of two glycine molecules is required for efficient receptor activation of the homomeric 1 GlyR [81] [82] and the homomeric 2 GlyR [52] . Legendre [83] proposed the existence of two glycine binding sites on heteromeric zebrafish GlyRs, whereas Burzomato et al. [84] proposed 3 binding sites on recombinantly expressed heteromeric 1 GlyRs.
There is abundant evidence that glycine binds in the ligand binding pocket. Residues in the principal binding domains A, B and C of the 1 subunit have all been shown to contribute to the coordination of glycine [20] . However, until recently there has been no systematic investigation into the glycine binding roles of residues in the complementary domains (D, E and F). Gruzdinska et al. [13] recently redressed this by identifying 2 amino acids in domain D (F63, R65) and one amino acid in complementary domain E (R119) that contribute to the glycine binding site. The same study also probed the role of the subunit in glycine binding. It showed that residues in principal binding domains B and C (E180, K223, Y225, Y231) and complementary domains D and E (R86, R154) of the subunit were also involved in the coordination of glycine [13] . These authors produced a structural homology model of a glycinebound 1 homomeric GlyR EC domain that incorporated all the above information. On the + side of the interface, the glycine amino group is coordinated by cation-pi interactions with the aromatic rings of F159 and F207, whereas the glycine carboxyl group is ligated by T204 and Y202 on the + side and R65 on the -side. The spatial arrangement of many of the 1 subunit glycine binding residues is shown in (Fig. 3) .
Prolonged agonist application induces desensitisation, a state where the channel remains closed in the continued presence of agonist. The rates of onset and recovery from desensitisation may be important for controlling the size, decay rate and frequency of synaptic currents [85] . A recent study has shown that GlyR desensitisation influences the amplitude of glycinergic synaptic currents at stimulation rates of > 1 Hz [86] . This finding comprises the first evidence that GlyR desensitisation may influence glycinergic synaptic function. Most kinetic schemes for the GlyR have ignored the effects of desensitisation due to its relatively slow rate of onset. However, two recent modelling studies that incorporated desensitised states into GlyR kinetic schemes concur that desensitised states can be reached from both singly and doubly liganded open states [82] [83] [84] [85] [86] . Several of the pharmacological agents described below appear to modulate the GlyR by changing the rates of onset and recovery from these desensitised states.
Phosphorylation
All phosphorylation sites identified thus far in different GlyR subunits are situated around the intracellular loop between M3 and M4. Protein kinase C (PKC) was shown to 32 P radiolabel 1 GlyR isolated from spinal cord in vitro and S391 was subsequently identified by peptide mapping as the site of PKC phosphorylation [87] . The surrounding sequence corresponds closely to the PKC consensus sequence and is conserved in subunits. Phorbol ester treatment of adult rat spinal cord cells in situ also resulted in 32 P radiolabelling of GlyR [88] . A putative protein kinase A (PKA) phosphorylation site was also identified in an alternatively spliced isoform of rat GlyR 1 mRNA ( 1 ins ; [88] [89] ). Treatment of adult rat spinal cord cells with forskolin effected radiolabelling of subunits with 32 P [88] . Significantly, in primary neuron spinal cultures, which were thought to express only 2 subunits, forskolin induced phosphorylation was not observed [88] . An 3 GlyR-specific PKA consensus sequence has also recently been identified [65] . While the glycine-activated current in HEK293 cells transfected with 3L homomers is inhibited following G protein activation and subsequent increase in cAMP levels, no inhibition is observed following mutagenesis of the 3 phosphorylation site [65] . A protein tyrosine kinase (PTK) consensus sequence motif was identified in the GlyR subunit [9] . Site-directed mutagenesis at the putative phosphorylation site, Y413F, was used to demonstrate a role for this tyrosine residue in the modulation of GlyR function by PTKs [90] . While the above studies demonstrate the possibility of GlyR phosphorylation in vivo, the physiological relevance of most of these phosphorylation events awaits clarification. As discussed below, reports of the functional effects of protein kinases and protein kinase activators on GlyR currents frequently produce inconsistent results.
PKA
Reports concerning the effects of PKA on glycine-activated current are often contradictory. The observed discrepancies may result from methodological differences, cell-type or GlyR subtypespecific effects, or from phosphorylation of GlyR protein modulators . An increase in glycine-activated current was observed after perfusion of spinal trigeminal neurons with either cAMP or cAMP-dependent PKA [92] [93] . Spontaneous phosphorylation of GlyR by endogenous PKA was also demonstrated [93] . While agonist sensitivity of GlyR did not change, cAMP-dependent phosphorylation was observed to increase the probability of channel opening [92] . An increase in glycine current was also seen following cAMP-treatment of Xenopus oocytes injected with rat brain mRNA [88] and following cAMP-treatment of embryonic spinal cord neurons [94] . However, in hypothalamic neurons, the amplitude of fast-desensitizing currents induced by high concentrations (30 μM -1 mM) of glycine was reduced after cAMP treatment [95] . An attenuation of the fast-desensitizing current was not observed when cAMP was added in conjunction with an inhibitor of PKA. In a more recent study, an enhanced desensitisation rate was observed after application of saturating concentrations of glycine to recombinantly expressed 1 GlyRs following pre-treatment with PKA or PKC [82] . Correspondingly, a moderation of desensitization (and deactivation) was observed following dephosphorylation with alkaline phosphatases.
As discussed above (Section 4), inhibitory glycinergic currents onto superficial dorsal horn neurons in spinal cord slices were suppressed by PGE 2 through a postsynaptic mechanism involving activation of the EP 2 receptor [64] . PGE 2 binding to the EP 2 receptor activates PKA via an increase in intracellular cAMP. Consistent with this, a PKA inhibitor reduced the inhibitory effect of PGE 2 on glycinergic inhibitory postsynaptic currents [64] . PGE 2 also inhibited glycine-activated current in HEK293T cells co-transfected with GlyR 3L and EP 2 receptor and no suppression was observed upon perfusion of a PKA inhibitor [65] . Furthermore, no inhibition was observed following mutation (S346A) of a putative 3-specific PKA phosphorylation site. Since inhibition of glycine-activated current was not observed with HEK293T cells co-transfected with GlyR 1 and EP 2 receptor, the specificity of the pathway for 3 was confirmed. PKC Again, reports of the effects of PKC on GlyR currents are often contradictory. Xenopus oocytes injected with rat brain mRNA and treated with phorbol ester show a time-dependent decrease in glycine current that was considered to be mediated by PKC [88] . Treatment of embryonic spinal cord neurons with phorbol ester also reduced the amplitude of glycine currents [94] . In contrast, PKC perfusion resulted in a potentiation of glycine-activated currents in trigeminal neurons [93] . The same authors also challenged the assumption of a specific effect of phorbol ester treatment on PKC. Albarran et al [96] subsequently demonstrated that inhibition of embryonic spinal cord neurons by phorbol ester was abolished by a PKC inhibitor, implying a specific PKC-mediated action. The authors conclude that the GlyR is inhibited or potentiated by PKC depending on neuronal type and location [96] . A recent report has also stressed the importance of temperature in PKC modulation [97] .
PTK
The glycine-activated current in cultured hippocampal neurons was potentiated during perfusion by the PTK, cSrc [90] . As expected for a PTK-specific effect, enhancement of glycine-activated current was not apparent in the presence of a PTK inhibitor. Tyrosine phosphorylation was also observed to enhance GlyR desensitization. In HEK293 cells expressing 1 GlyRs, the run-down of glycine currents was reduced and desensitization was increased after perfusion with cSrc [90] . No corresponding reduction in the run-down of glycine current (or increase in desensitization) was observed in 1 GlyRs incorporating the Y413F mutation in the subunit. Furthermore, a specific inhibitor of Src affected WT 1 GlyR currents only, confirming a role for cSrc phosphorylation in receptor potentiation.
CaMKII
Although there are no CaMKII phosphorylation consensus sites present on any GlyR subunits, several studies demonstrate modulation of GlyR function through a CaMKII-dependent mechanism [98] [99] . The target of CaMKII is presumably an unknown accessory protein.
Zn

2+
Zn
2+ is a modulator of both excitatory and inhibitory synaptic function (see [100] for a review). Free Zn 2+ co-localizes with neurotransmitters in presynaptic vesicles at 'zinc-enriched' terminals in brain and spinal cord neurons [101] [102] [103] [104] . Zn 2+ is released from these vesicles in a calcium-dependent manner [105] and Zn 2+ concentrations in the synaptic cleft subsequently reach 10 μM [100] . Consistent with the hypothesis that Zn 2+ is capable of modulating glycinergic inhibitory postsynaptic currents in vivo, co-localization of Zn 2+ with glycine (and GABA) in presynaptic vesicles of spinal neurons has been demonstrated [103] [104] . Indirect evidence in favour of the proposition that Zn 2+ is a physiologically relevant neuromodulator of glycine-evoked currents is plentiful. An effect of Zn 2+ on glycinergic inhibitory postsynaptic currents has been observed in situ [106] . In one study, Zn 2+ and Zn 2+ chelators induced opposing effects on glycinergic miniature inhibitory postsynaptic current magnitude [106] . Zn 2+ has also been demonstrated to biphasically modulate GlyRs in a concentration-dependent manner in dissociated neuronal cultures and heterologous expression systems [107] [108] [109] . Recently, two discrete binding sites for Zn 2+ have been identified and extensively mapped [108] [109] [110] [111] [112] .
Zn 2+ Potentiation
GlyR current is enhanced at sub-μM concentrations of Zn 2+ [113] . The EC 50 for Zn 2+ potentiation is less than 100 nM [106] [107] [108] [109] [110] [111] . Indeed, even basal (low nM) Zn 2+ concentrations were shown to increase glycinergic currents [106] . The binding of Zn 2+ to this high-affinity site results in a decrease in the dissociation rate constant for agonist [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] . A consequent increase in the apparent affinity for agonist is proposed to explain the observed potentiation effect [109] [110] [111] [112] [113] [114] [115] . However, evidence at odds with this proposition is provided by analysis of several mutant receptors [114] . The glycine binding affinity of a receptor mutated at L274 in the M2-M3 linker is enhanced in the presence Zn 2+ . However, Zn 2+ potentiation of glycine-gated current is abolished in this receptor [114] . These results suggest a role for L274 in the allosteric pathway linking the potentiation site and the receptor gate. In contrast to the results obtained with glycine, Zn 2+ does not enhance the apparent taurine binding affinity of L274A mutant receptor, but Zn 2+ still strongly potentiates taurine-gated currents. Thus, Zn 2+ potentiation can be dissociated from its effects on agonist binding through mutation of residues involved in receptor gating. Similar results were obtained using a GlyR mutated at M246 in the intracellular M1-M2 domain (another region with a crucial role in the agonist transduction pathway). Disruption of potentiation in this mutant receptor provides additional evidence for the importance of an allosteric potentiating pathway. Furthermore, while Zn 2+ is able to enhance glycine binding affinity in the D80A mutant receptor, Zn 2+ potentiation is once more abolished [114] . Again, taurine activated responses are still potentiated by Zn
2+
. These results suggest that Zn 2+ potentiation of taurine and glycine gated currents occurs via an allosteric mechanism that is independent of the mechanism by which Zn 2+ enhances agonist binding. Nonetheless, it is important to note that potentiation may occur through different mechanisms for glycine and taurine.
The location of the high affinity Zn 2+ potentiation site has recently been identified [111] . Homomeric 1 and 2 GlyRs were demonstrated to have differential sensitivities to Zn 2+ and a comparison of their respective sequences identified 2 E201 as a determinant of Zn 2+ potentiation sensitivity. The 2 E201D mutation was shown to increase the Zn 2+ -sensitivity of 2 GlyRs to 1 GlyR levels. The importance of an aspartic acid residue at this location was confirmed by mutagenesis of the equivalent 1 residue, D194A. As expected, D194A GlyRs were insensitive to Zn 2+ potentiation over a wide Zn 2+ concentration range (mutagenesis was performed on a "reduced inhibition" background). Consistent with a direct role in coordination, D194 was demonstrated to be necessary for both glycine-activated and taurine-activated responses [114] . Two additional 1 GlyR residues, E192 and H215, were hypothesised to be implicated in potentiation based on a model of the EC domain of the 1 GlyR [111] . E192, D194, and H215, are all predicted to reside within 5 Å of the putative Zn 2+ -coordination site on the external face of the outer -sheet. The surface location of D194 and H215 was further confirmed by cysteine mutagenesis of these residues and subsequent modification by the sulfhydryl-reactive compound, MTSEA. However, MTSEA modification of E192C did not eliminate potentiation. The authors suggest a role for the sidechains of D194 and H215 in co-ordinating Zn 2+ and a possible role of the backbone at position 192. Coexpression studies indicate that the subunit is not able to compensate for the elimination of Zn 2+ potentiating sites in the subunit. The sidechain of an additional residue located in the cys-loop, T151, has an important role in determining the "magnitude and direction of output" (potentiation vs inhibition) from the Zn 2+ potentiation site. The demonstrated importance of the cys-loop in agonist gating is consistent with a role for T151 in signal transduction [116] . As noted above, the cys-loop directly interacts with the TM2-TM3 linker, and mutations in the TM2-TM3 linker also affect Zn 2+ potentiation [114] [115] [116] [117] .
Zn 2+ Inhibition
Glycine concentration response curves obtained at different Zn 2+ concentrations demonstrate that Zn 2+ inhibits glycine activity via a competitive mechanism [108] [109] [110] [111] [112] . Thus, at inhibitory Zn 2+ concentrations, individual concentration response curves are displaced in parallel with no reduction in maximum current [112] . It is concluded that glycine binding and inhibitory Zn 2+ binding sites are non-overlapping and mutually exclusive. The Zn 2+ inhibitory binding site has now been extensively mapped . The contribution of EC domain histidine residues in coordinating inhibitory Zn 2+ was first demonstrated by Harvey et al [108] . At pH 5.4, Zn 2+ inhibition of glycine receptor was selectively abolished by protonization of histidine residues. These results were also confirmed by treatment with diethylpyrocarbonate, a histidine modifying reagent, and then by mutagenesis of individual histidine residues. The 1 subunit residues, H107 and H109, were consequently identified as essential for coordination of inhibitory Zn
2+
. Inhibition is almost completely abolished in the H109A 1 GlyR [108] [109] [110] . In contrast, inhibition is only reduced by a factor of 15 in the H107A 1 GlyR. The results suggest that coordination of Zn 2+ is not perfectly symmetrical [112] . The 1 subunit H107A/ H109A double mutant receptor is completely insensitive to Zn 2+ inhibition [110] .
According to a model of the 1 homomeric GlyR based upon the structure of AChBP [118] , H107 and H109 were situated near to the central water-filled cavity of the EC domain and close to the interface between subunits (Fig. 3) . This model led the authors to propose that H107 and H109 might coordinate Zn 2+ across the subunit interface, and that the ionic bridge formed between the two histidine residues and Zn 2+ could block relative movement of subunits, and prevent channel opening. Confirmation that the Zn 2+ inhibition site was formed at the intersubunit interface was provided by co-expression of individual 1 H109A mutant receptor and 1 H107A mutant receptor [110] . While reduced sensitivity to Zn 2+ inhibition was observed upon expression of individual 1 H107A and 1 H109A mutant receptors, inhibition was restored upon coexpression of both mutant subunits. Indirect evidence that the ionic bridge involving Zn 2+ is able to stabilize the closed state has also been provided. The greater potency of inhibition after preincubation with Zn 2+ and the delayed onset of inhibition are both consistent with the above hypothesis [110] [111] [112] .
Zn
2+ inhibition of the 1 GlyR is an order of magnitude more sensitive than Zn 2+ inhibition of the 2 or 3 GlyRs [112] . A comparison of subunit sequences indicates residues equivalent to 1 H107 are replaced by an asparagine residue ( 2 N114 or 3 N107). Substitution of asparagines by histidines (i.e., 2 N114H; 3 N107H) was shown to increase sensitivity to Zn 2+ inhibition of 2 and 3 GlyRs to the level seen in the 1 GlyR. The reverse mutation ( 1 H107N) was observed to decrease sensitivity to Zn 2+ inhibition greater than 10-fold. An asparagine residue replaces 1 H107 in the subunit also ( N130). Interestingly, sensitivity to Zn 2+ inhibition of 1 H107N was recovered after co-expression with N130H [112] . Although it was previously demonstrated that coordination of inhibitory Zn 2+ from the -face of the subunit (across the / interface) was not likely, [110] , the + face of the subunit (across the / interface) is able to coordinate Zn 2+ [112] . Indeed, in 2/ heteromers, a two-fold increase in sensitivity to inhibition is observed relative to 2 homomer, although a similar result was not observed for 1 and 1 GlyRs. In addition to 1 H109, another residue on the -face, 1 T133, was also demonstrated to be essential for Zn 2+ coordination [112] . The results stress the importance of subunit residues on the -face. The residues H109 and T133 on the -face of the 1 subunit are proposed to be responsible for transducing the inhibition signal via the subunit throughout the receptor [112] . In contrast, 1 H107 (or the equivalent subunit residue) on the + face is involved only in coordination. The results suggest that the subunit may only subtly influence the potency of zinc [112] .
Cannabinoids
The endogenous cannabinoid (endocannabinoid) system is a ubiquitous lipid signalling system with numerous modulatory effects throughout the central nervous system. Endocannabinoids have a dual modulatory effect on glycinergic inhibitory synapses [119] [120] [121] . Endocannabinoids mediate retrograde signalling at the glycinergic inhibitory synapse [122] . Following depolarisation of the presynaptic terminal, they are rapidly released from postsynaptic neurons and subsequently mediate presynaptic inhibition of glycine release in an activity-dependent manner. This process, termed 'depolarization induced suppression of inhibition', is mediated by presynaptic CB1 receptors. Recently, direct post-synaptic modulation of GlyRs by endocannabinoids has also been demonstrated [119] [120] [121] [122] [123] . The amplitude of the glycine-induced current was inhibited in isolated hippocampal pyramidal and Purkinje cerebellar neurons by anandamide and 2-arachidonylglycerol in a reversible and concentration dependent manner [123] . The structure of anandamide is shown in (Fig. 5) . Since the effect was not abolished by CB1 receptor inhibitors or G protein inhibitors, a direct interaction between these endocannabinoids and GlyRs was proposed. In addition to the observed inhibition, anandamide and 2-arachidonylglycerol also altered the kinetics of rise-time, desensitization, and deactivation of glycinergic currents. Conversely, anandamide and 9-tetrahydrocannabinol were observed to increase the amplitude of glycine-induced currents in Xenopus oocyte-expressed 1 homomeric and 1 heteromeric GlyRs [120] . Again, GlyR modulation was reversible, concentration dependent, and independ- Fig. (5) . Structures of representative compounds with bioactivity at the GlyR.
Please provide original ChemDraw file in CDX format ent of the CB1 receptor. Furthermore, the anandamide and 9-tetrahydrocannabinol were also observed to potentiate the glycineinduced current in acutely dissociated rat ventral tegmental area neurons. Since the magnitude of the potentiation decreased with increasing concentrations of glycine, the effect appears to be mediated by a sensitisation of the receptor to glycine. Importantly, GABA A Rs were not potentiated by cannabinoids in either system. This seems to rule out a nonspecific effect mediated through a change in membrane properties [121] . The discrepancy between the two studies is possibly the result of the lower glycine concentrations used in the study reporting potentiation. Alternatively, the discrepancy may result from differences in subunit composition.
Ca
2+
Glycine-induced currents were potentiated by Ca 2+ influx in both spinal cord neurons and in HEK293 cells co-expressing 1 GlyRs and Ca 2+ -permeable channels [121] . The Ca 2+ induced potentiation was characterized by an increase in GlyR sensitivity to subsaturating glycine concentrations. Although potentiation was demonstrated to be very fast (< 100 ms), a direct binding of Ca 2+ to the receptor was ruled out. Since the Ca 2+ -dependent potentiation persisted following inhibition of calmodulin-dependent kinase II and following application of a calmodulin antagonist, a Ca 2+ -dependent potentiation mediated via calmodulin-dependent kinase II was also ruled out. Because direct application of Ca 2+ to the exposed surface of inside-out patches caused irreversible activation, the authors proposed that potentiation occurs following dissociation of an unknown Ca 2+ binding protein constitutively bound to the intracellular M3 -M4 domain. A role for upstream G protein pathways in rapid Ca 2+ -dependent potentiation was excluded following application of specific inhibitors of G protein pathways. However, comparable increases in channel open probability and GlyR apparent affinity were observed upon the direct binding of G protein subunits to the 1 GlyR [124] . Although the possibility of Ca 2+ -dependent potentiation through direct binding of subunits was not unambiguously excluded in the pharmacological experiments of Fucile et al. [125] , the irreversible activation of the effect in insideout patches is not readily consistent with the involvement of G protein subunits.
Neurosteroids
Neurosteroids are steroid hormones synthesized in the brain that can modulate neuronal function through both gene expression and by direct modulation of neuronal excitability [126] . GlyRs and GABA A Rs display different sensitivities to many neuroactive steroids [127] [128] [129] . However, most neurosteroids are active at a wide range of receptors so their potential as therapeutic agents is limited [126] . Pregnenolone Pregnenolone (PREG) is the direct precursor of pregnenolone sulphate (PREGS), progesterone, and dehydroepiandrosterone (DHEAS). Its structure is shown in (Fig. 5) . PREG potentiated glycine-induced current in Xenopus oocyte-expressed 1 GlyRs in a non-competitive fashion with an EC 50 near 1.4 μM [130] . In contrast, PREG had no effect on 2 GlyRs and PREG potentiation was eliminated following co-expression of 1 with the subunit. PREGS PREGS Regulates neuronal excitability by acting on both inhibitory and excitatory amino acid receptors [131] . PREGS inhibited a range of GlyR subtypes with an IC 50 in the 2 -20 μM range upon expression in Xenopus oocytes [130] . The inhibitory potency of PREGS was however higher for 1 relative to 2 homomeric GlyRs [130] . The inhibitory potency of PREGS was also decreased upon co-expression of subunits with the subunit [130] . PREGS parallel shifted the glycine dose response curves to the right, suggestive of a competitive inhibitory mechanism rather than a channel block mechanism. PREGS inhibition was also observed on cultured chick spinal neurons [132] .
Progesterone
Progesterone specifically inhibited 2 GlyR homomers in a mixed competitive and noncompetitive manner [130] . Competitive inhibition by progesterone was also observed on glycine-induced currents in chick spinal cord neurons [132] . The progesterone binding site was suggested to be discrete from that of PREGS on the basis of their differing modes of action. Dehydroepiandrosterone Dehydroepiandrosterone (DHEAS). The pattern of inhibition of glycine-induced currents by DHEAS was identical to that observed with PREGS. However, DHEAS was consistently less potent than PREGS at most recombinant GlyR subunit combinations [130] .
G Protein Pathways
A role for G protein pathways in the modulation of GlyR function was clearly demonstrated in both dissociated spinal trigeminal neurons and cultured embryonic spinal cord neurons [92] [93] [94] . A potentiation of current amplitude was observed upon application of non-hydrolyzable GTP analogues. The observed potentiation was mimicked by cAMP and PKA and is thought to involve Gs protein pathways. A novel modulation of GlyR function through direct binding of G protein subunits has since been described [124] . The amplitude of glycine-induced currents in HEK293 cell-expressed 1 GlyRs was increased after perfusion with a non-hydrolyzable GTP analogue [124] . A potentiation of glycine-induced current (but not GABA-induced current) and an enhancement of glycinergic synaptic current were also observed in cultured embryonic spinal cord neurons [124] . GlyR potentiation was found to be dependent on the G dimeric complex. G complex was able to enhance the glycine-induced current by increasing the apparent affinity for glycine. Furthermore, direct application of the G complex increased the channel open probability during single channel recordings. A direct interaction between GlyR and the G complex was convincingly demonstrated by co-immunoprecipiation [124] . The results raise the possibility of regulation of GlyR by diverse pathways through different G protein-coupled receptors.
MOLECULAR PHARMACOLOGY
Representative structures of compounds discussed in this section are given in (Fig. 5) .
Positive Allosteric Modulators Ivermectin
Ivermectin which is commonly used as an antihelminthic in agriculture, veterinary and human practice, has positive allosteric modulatory effects on most cys-loop receptors (reviewed in [133] ). Pre-application of low concentrations (0.03 μM) of ivermectin potentiated the magnitude of subsequent glycine responses at recombinant 1 GlyRs, but at higher concentrations (> 0.03 μM) it directly and irreversibly activated these receptors [133] . Ivermectin appears to activate the receptor via a different mechanism to glycine as GlyRs that are completely desensitised to glycine remain available for activation by ivermectin [133] .
Tropisetron and Analogues
Several structurally related 5HT 3 receptor antagonists have been shown to exert potentiating and/or inhibitory effects on the GlyR. Those compounds exerting both potentiating and inhibitory effects include bemesetron, tropisetron, zatosetron and LY278584, whereas those that induce inhibition only include cocaine, atropine, zacopride, ondansetron and granisetron [134] [135] . Tropisetron, which is used clinically for treating postoperative and chemotherapy-induced emesis, is the most thoroughly investigated of these compounds. Tropisetron has been shown to potentiate glycine currents at nanomolar concentrations, but produces inhibition at higher (micromolar) concentrations [136] . High potency tropisetron potentiation of the GlyR requires the presence of the subunit [137] . Although 1 GlyRs exhibit tropisetron potentiation, 2 GlyRs ex-hibit no potentiation unless co-expressed with the subunit [137] . Tropisetron and its analogues are perhaps the most promising therapeutic lead compounds yet identified at the GlyR due to their excellent oral bioavailability and the high affinity of their potentiating effects. Indeed, there is evidence that tropisetron and other 5-HT 3 R antagonists exert antinociceptive actions in the spinal cord [138] .
Structure-activity analyses of tropisetron analogues have provided some insight into the tropisetron structural moieties required for potentiation and inhibition [134] [135] [136] [137] [138] [139] [140] [141] . One such analysis concluded that an aromatic ring, a carbonyl group and a tropane nitrogen are required for glycinergic potentiation [134] . Tropisetron has recently been used as a template to construct a range of analogues, many of which also had nanomolar affinity for the GlyR [141] . This study also refined the tropisetron pharmacophore model to include putative GlyR interactions as follows: (a) an aromatic ring harboured by a lipophilic region of the binding site, (b) an attached ester group fixed via hydrogen bonds, and (c) a basic nitrogen of the tropane ring interacting electrostatically with the receptor.
To date, however, there is no information as to the location of the tropisetron contact sites on the GlyR. Although little is known about tropisetron binding at the 5-HT 3 R, recent studies have produced a consensus model for the binding of the structurally related compound, granisetron, in the ligand binding pocket [142] [143] [144] . It should be noted, however, that granisetron binds in the 5-HT 3 R ligand-binding pocket with nanomolar affinity [143] [144] [145] , whereas it inhibits the GlyR with an IC 50 of around 100 μM [140] . Currently, there are no lcues as to whether tropisetron binds in the GlyR ligand-binding pocket in the potentiating mode, the inhibitory mode, or both. Thus, the extent to which the 5-HT 3 R granisetron binding site provides a useful template for the GlyR tropisetron binding sites remains to be seen. However, a comparison of the binding affinities and modes of action of tropisetron analogues at the 5HT 3 R and GlyR reveals that their respective binding sites are not identical. This appears to bode well for the discovery of GlyRspecific tropisetron analogues.
Alcohols and Anaesthetics
Rather high ethanol concentrations (50 -100 mM) are required to potentiate the GlyR. Since alcohol intoxication occurs at concentrations an order of magnitude lower than this, the GlyR is probably not its primary pharmacological target. Among n-alcohols, the magnitude of GlyR potentiation is dependent on the alcohol chain length with a maximum occurring at an n of 10 -12 [146] . Further increases in n result in a decrease in effectiveness at the GlyR. This cut-off phenomenon supports the idea of an alcohol binding site located within a spatially-restricted pocket [146] . This notion was further supported by the demonstration that an increase the volume of the sidechain at an alcohol binding residue was accompanied by a decrease in the cut-off maximum for n-alcohols [147] . Low (EC 5 -EC 10 ) glycine concentrations are generally required to see the alcohol potentiating effect at recombinantly expressed GlyRs. Nevertheless, 100 mM ethanol has been shown to significantly potentiate glycinergic inhibitory miniature postsynaptic currents in hypoglossal motor neurons [148] . GlyR ethanol enhancement has recently been shown to be mediated by an increase in the number of activated channels, a decreased latency to first channel opening and a decrease in channel closing rate, all suggestive of a mechanism whereby ethanol increases the glycine affinity [149] .
A range of volatile anaesthetics also exerts potentiating effects on GlyRs. In both recombinant 1 GlyRs and in GlyRs endogenously expressed in cultured medullary neurons, the following rank order of anaesthetic potentiating potency has been observed: halothane, isofluorane, enfluorane, F3 > methoxyfluorane, sevofluorane [146] . Despite these effects, other neurotransmitter-gated ion channels, particularly GABA A Rs and excitatory glutamate receptors, are considered to represent more clinically important anaesthetic targets [150] .
Alcohols and anaesthetics both act at a common binding site on the GlyR and GABA A R. Site-directed mutagenesis of the 1 GlyR identified S267 in the M2 domain and A288 in the M3 domain as crucial mediators of the potentiating response to both ethanol and enfluorane [36] . These residues were hypothesised to face each other across a water-filled cavity in the GlyR TM domain that is physically distinct from the ion channel pore (Fig. 4) . When S267 and A288 were simultaneously substituted by cysteines, the double mutant 1 GlyR exhibited a progressive rundown in glycine responsiveness and a tonic leak activity that was blocked by strychnine [151] . Application of a disulfide bond reducing agent abolished the leak and restored normal glycine responsiveness. These results indicate that S267C and A288C crosslink spontaneously, implying a close physical proximity between the two residues [151] .
Strong evidence has emerged to support the view that these residues do indeed contribute to the coordination of both alcohols and anaesthetics. For example, the S267C mutant 1 GlyR is irreversibly potentiated by either propyl methanethiosulfonate (PMTS) or by the sulfhydryl-containing anaesthetic, propanethiol, under oxidising conditions [152] . Since this effect was absent at unmutated receptors, it is likely that both compounds cause the irreversible potentiation by covalently crosslinking with S267C. Furthermore, after modification by either compound, the mutant receptor was no longer able to be potentiated by alcohols or anaesthetics [152] . Together, these observations make a strong case for these compounds binding at or near S267.
The homomeric 1 GlyR contains 5 structurally equivalent alcohol and anaesthetic binding pockets. In an extension to the approach outlined in the previous paragraph, Mihic and colleagues presented evidence that a single bound anaesthetic molecule per receptor is sufficient to enhance GlyR function [153] . Their idea was to transfect WT and S267C mutant 1 GlyR cDNAs in such a ratio that it was highly unlikely that more than one mutant subunit would be present in each pentameric receptor. They found that PMTS could significantly potentiate receptor function even when the ratio of WT to mutant cDNA was 200:1.
A recent study investigated the state-dependent changes in the reactivity of sulfhydryl-specific MTS-containing compounds with 1 GlyRs containing introduced cysteines at and around the alcohol binding site [154] . Receptor activation by glycine was found to increase the accessibility of mutated amino acids to the MTS reagents. At some positions, short chain MTS reagents could react in both the closed and open states but longer chain reagents could react only in the open state. This suggests that binding site volume is increased in the open state. Together, the results suggest that alcohols may promote an open state-like configuration in this region and thereby bias the entire receptor structure towards the activated state [154] . This could in turn bias the glycine binding site towards the activated configuration, thereby increasing glycine affinity.
An increase in atmospheric pressure was recently shown to reversibly antagonize the potentiating response to high (40-200 mM) ethanol concentrations at the 1 GlyR [155] . The response to lower ethanol concentrations (10 and 25 mM), however, remained unaffected. Because this pressure sensitivity was abolished by the A52S mutation, the authors concluded that there may be more than one site for ethanol binding in the GlyR [155] . The two sites may be distinct in terms of their ethanol sensitivity, subunit specificity and response to pressure.
Aguayo and colleagues have proposed a completely different mechanism for alcohol regulation of GlyRs. As discussed in a recent review [156] , they propose that alcohol modulates both GlyRs and GABA A Rs by modifying the ability of protein kinases or G protein subunits to interact with sites in the large intracellular domain. This model posits that mutations to the putative alcohol binding sites, S267 and A288, act by non-specifically disrupting this process.
Alkylbenzene Sulfonate
Alkylbenzene sulfonate a detergent commonly used in commercial cleaning products, had strong potentiating effects on submaximal currents in 1 GlyRs recombinantly expressed in Xenopus oocytes [157] .
Butyrolactones
The anticonvulsant butyrolactone, -ethyl -methyl--thiobutyrolactone ( EMTBL), potentiates the response to submaximal glycine concentrations in Xenopus oocyte-expressed 1 homomeric GlyRs but inhibits these responses in 3 homomeric GlyRs [158] . Coexpression of 1 and subunits has no affect on potentiation, whereas coexpression of 3 and subunits removes the inhibition. There are so far no clues as to the location of the potentiation site, but the inhibitory site appears to be located deep in the pore as EMTBL inhibition is abolished by the 3 subunit T6'F mutation. As millimolar concentrations of EMTBL are required to elicit significant potentiating effects, its potential as a therapeutic lead compound seems limited.
Chloromethiazole
Chloromethiazole potentiated glycine-gated Cl -currents in cultured murine spinal neurons at 30-100 μM concentrations [159] . This compound, which has sedative, hypnotic and anticonvulsant activities, is widely used to treat alcohol withdrawal symptoms including delirium tremens.
Dideoxyforskolin
Dideoxyforskolin is a forskolin analogue that is unable to stimulate adenylate cyclase. At low micromolar concentrations, it increases the magnitude of submaximal glycine-gated currents in cultured spinal neurons [160] . However, at saturating or nearsaturating glycine concentrations, no potentiation was observed and a weak slow onset inhibition was seen.
Dihydropyridines
Dihydropyridines are widely used to treat cardiovascular hypertension. They are considered highly selective antagonists of L-type calcium channels at nanomolar concentrations, although at micromolar concentrations they have been shown to affect a variety of other channel types. The dihydropyridines, nitrendipine and nicardipine, exerted both rapid onset potentiating effects and slower onset inhibitory effects on spinal cord neuron GlyRs at low micromolar concentrations [161] . Both potentiating and inhibitory effects seemed to occur over the same concentration range. Another dihydropyridine, nifedipine, exerted only inhibitory effects.
Ginsenosides
Ginsenosides the active ingredients of the Panax ginseng plant, can modulate the function of many ion channel types (reviewed in [162] ). Ginsenoside-Rb3 inhibited GlyR currents in dissociated rat hippocampal neurons with an IC 50 near 0.1 μM [162] . In contrast, an earlier study that investigated the effects of a series of 8 ginsenosides found that the most active compound, ginsenoside-Rf, potentiated Xenopus oocyte-expressed recombinant 1 GlyRs with an EC 50 near 50 μM [163] . These differential effects that occur despite close structural similarities of the ginsenosides suggest these compounds may be useful as structural and functional probes of the GlyR.
Menthol
Both the + and -entaniomers strongly potentiated currents activated by low (EC 20 ) glycine concentrations in 1 GlyRs recombinantly expressed in Xenopus oocytes [164] . Both compounds were effective at concentrations > 10 μM, and they acted by inducing a leftward shift in the glycine EC 50 value.
Minaxolone
The synthetic steroids, minaxolone, alphaxalone and ORG20559 significantly potentiated homomeric 1 GlyRs recombinantly expressed in Xenopus oocytes [165] . Minoxalone exerted the most dramatic effect, potentiating EC 10 glycine currents by 1200%, with an EC 50 value of 28 μM. This compound also has strong potentiating effects on recombinant 1 2 2L GABA A Rs [165] .
Penicillin G
Penicillin G effects on glycine currents in acutely dissociated rat hypothalamic neurons were investigated using the whole cell patch clamp technique [166] . When co-applied with glycine, penicillin G caused inhibition. However, when glycine alone was introduced following a co-application of penicillin G plus glycine, a strong rebound potentiation was observed. Under certain conditions, this rebound current could be larger than the saturating glycine current amplitude.
Pentobarbital
Pentobarbital a barbiturate, is well known as a potent enhancer of GABA A R currents. It is effective as an anticonvulsive, hypnotic and anaesthetic drug, although for most clinical applications it has been superceded by the much safer benzodiazepines. In the presence of an EC 50 glycine concentration, 10 μM pentobarbital modestly potentiated currents carried by 1 GlyRs recombinantly expressed in HEK293 cells [167] . In contrast, pentobarbital concentrations higher than 300 μM caused a slow onset inhibition. An off current was also observed upon removal of glycine and pentobarbital, suggesting that the inhibition was mediated by open channel block [167] . This off current delayed the rate of channel closing, an effect which may prolong glycinergic synaptic currents and increase the potential for temporal summation.
Riluzole
Riluzole a sedative and anticonvulsant, has complex actions on the nervous system and is used clinically to treat amyotrophic lateral sclerosis. At 10 μM, it inhibited the mean amplitude of evoked glycinergic inhibitory postsynaptic currents in hypoglossal motor neurons by 87% [168] . It also inhibited recombinant 1 GlyRs by promoting receptor entry into a desensitised state [169] . Paradoxically, however, riluzole prolonged the time course of simulated glycinergic synaptic currents [169] . As this effect would serve to enhance glycinergic neurotransmission by improving the efficacy of temporal summation, it is reasonable to classify riluzole as a potential lead compound for the development of novel GlyR positively modulating substances.
Tamoxifen
Tamoxifen is a selective estrogen receptor modulator that is used clinically for treating breast cancer. When applied at concentrations of 0.2 -5 μM, it strongly potentiated submaximal GlyR responses in cultured spinal neurons by inducing a leftward shift in the glycine EC 50 value [160] . Its potentiating effects were more dramatic when it was pre-applied for 2-3 minutes before glycine addition, although it produced a weaker potentiation when coapplied with glycine. Tamoxifen potentiation was observed to be larger than that induced by other GlyR potentiating agents, including dihydropyridines, tropisetron analogues and ethanol [160] . Low micromolar concentrations of tamoxifen also increased the magnitude and frequency of spontaneous synaptic glycinergic synaptic currents recorded from voltage-clamped hypoglossal motoneurons in rat brainstem slices [170] .
Antagonists
Strychnine and analogues
The central role of multicyclic plant alkaloid, strychnine, in the initial characterisation and purification of the GlyR has been discussed above. Strychnine inhibits all known GlyR isoforms with nanomolar affinity and strychnine sensitivity remains the definitive means of pharmacologically identifying glycinergic synaptic currents. Strychnine is a classical competitive antagonist and abundant evidence indicates that it binds in the EC agonist binding pocket. For example, early studies showed that mutations in the 1 GlyR principal ligand binding domains B and C (i.e., G160E, Y161A, K200A, Y202A) caused drastic reductions in strychnine sensitivity [20] . These residues either coincide with, or lie adjacent to, glycine binding sites. Grudzinska and colleagues have recently identified several additional 1 subunit mutations that dramatically reduce sensitivity to both glycine and strychnine [13] . These include F207A in ligand binding domain C, E157D in ligand binding domain B, F63A in ligand binding domain D and R131A in ligand binding domain E. Several other mutations were found that affected either glycine-or strychnine-sensitivity, but not both. Based on these results, a model of strychnine binding was proposed [13] . Interestingly, successful strychnine docking required that binding domain C be positioned in an 'opened' configuration, similar to the position the homologous domain adopts in the unliganded state of the Torpedo nAChR 1 subunit [19] . A number of strychnine structure activity analyses have been performed over the years. A recent detailed analysis [171] found that virtually all strychnine modifications result in a loss of affinity, and that none significantly improved affinity or conferred significant selectivity between 1 and 1 GlyR subtypes.
Picrotoxin
Picrotoxin, a macrocyclic plant alkaloid, is an equimolar mix of two components, picrotin and picrotoxinin, which differ only by a single group. Picrotoxin has proved to be a rather non-specific inhibitor of anionic cys-loop receptors. Nevertheless, the mechanism of picrotoxin inhibition of 1 GlyRs appears to be different from picrotoxin inhibition of the GABA A R where it behaves as a noncompetitive antagonist and channel pore blocker [172] . In 1 homomeric GlyRs, picrotoxin inhibitory potency decreases as glycine concentration is increased and picrotoxin inhibition exhibits no usedependence . Several 1 mutants that transform the mode of picrotoxin inhibition have been identified. Serine 15' in the M2 domain was identified as an important determinant of usefacilitation [175] as the 1 subunit S15'Q mutation converts picrotoxin into a non-competitive antagonist. Similarly, picrotoxin inhibition of the 1 subunit incorporating mutations to R19' was demonstrated to be non-competitive [173] and use-dependent [38] . On the basis of these experiments, it seems likely that mutations to the 15' and 19' residues introduce non-specific structural changes to the pore which affect the conditions under which picrotoxin can access its site. Interestingly, although 2 subunits are almost identical to 1 subunits throughout M2 and the M2 -M3 loop (apart from the G2'A substitution), picrotoxin inhibition of WT 2 GlyR is use-dependent [176] . On the whole, the evidence suggests picrotoxin may be acting as an allosteric GlyR inhibitor. Indeed, an analysis of the picrotoxin sensitivity of sulfhydryl reactivity rates for cysteine mutants (R271 -K276) in the 1 GlyR M2 -M3 loop suggests a specific conformational change in this domain occurs upon picrotoxin binding [38] . An allosteric model of picrotoxin binding has also been proposed on the basis of its interaction with the 2 GlyR [176] .
Experiments with the R271C mutant 1 GlyR provide strong evidence that picrotoxin binds in the channel pore [38] . As full recovery from picrotoxin inhibition required reopening of the R271C 1 pore, picrotoxin was shown to be trapped in the pore upon removal of glycine. Picrotoxin was also shown to be trapped in the pore of WT 2 GlyR [176] . The importance of the M2 domain 2' and 6' residues (Fig. 4) as determinants of picrotoxin sensitivity has been demonstrated in a variety of cys-loop receptors [177] . The corresponding residues in the 1 GlyR, G254 (2') and T258 (6'), are exposed in the channel lumen in the open state [174] .
1 homomers were more sensitive to picrotoxin inhibition than 1 heteromers, and picrotoxin sensitivity in 1 GlyRs could be restored by substitution of subunit 6' phenylalanines with the corresponding 1 subunit 6' threonines [174] [175] [176] [177] [178] . In addition, picrotoxin resistance was conferred to the 1 homomer T6'F mutation. While 2' mutations were revealed to only indirectly affect picrotoxin sensitivity, possibly through localized structural distortion, the T6' residue was demonstrated to be a critical determinant of picrotoxin sensitivity [174] . This ring of threonine residues at the 6' position is required for high picrotoxin sensitivity throughout the cys-loop receptor family [174] .
Molecular modelling studies suggest that picrotoxin can indeed bind at the 2' -6' level of anionic cys-loop receptors [172] [173] [174] [175] [176] [177] [178] [179] . Both modelling studies broadly identify several important interactions. In particular, the hydroxyl groups of T6' residues contribute important H-bonds to picrotoxin oxygens. It was noted that the amphipathic nature of G2' could allow both hydrophobic interactions between apolar backbone methylene atoms and the isoprenyl group of picrotoxinin, and hydrophilic interactions between polar backbone atoms and the OH of picrotin (possibly via bridging water molecules). The above proposal would explain the lack of discrimination of 1 between the two components of picrotoxin. Conversely, hydrophobic methyl groups of the GABA A R A2' residue facilitate discrimination between the two components of picrotoxin. As the 2 and 3 GlyR 2' residues are also alanines, it is possible that these receptors may also be able to discriminate between picrotoxin components. The modelling studies also provide an estimation of channel pore diameter (8.5 Å) at the level of the binding site [177] . Due to its subunit specificity, picrotoxin has long been used as a pharmacological tool for the identification of subunitcontaining GlyRs.
Ginkgolides and Bilobalide
The ginkgolides A, B, C and J and bilobalide are the active constituents of Ginkgo biloba extracts and have been shown to inhibit native neuronal GlyR channels [180] [181] . These molecules are all are highly oxygenated terpene trilactone type caged molecules. Ginkgolides A, B, C, and J differ only in the number and placement of hydroxyl groups. Ivic et al [180] proposed a similarity between the structures of ginkgolides and PTX on the basis of a common spatial arrangement of characteristic chemical moieties. Inhibition of GlyR by ginkgolides has been shown to be usedependent, voltage-dependent and glycine-independent [180] [181] [182] , which are all classical properties of pore blocking molecules. In contrast, bilobalide inhibition is use-dependent, voltageindependent and glycine-dependent [182] . Both ginkgolides and bilobalide can be trapped in the pore of the R271C mutant 1 GlyR . On the basis of these results, ginkgolides and bilobalide are both proposed to act as channel blockers. The subunit specificity of inhibition by these compounds has recently been investigated in recombinantly expressed receptors [182] [183] and the subunit specificity of each compound will be considered in turn.
Ginkgolide A (GA) exhibits a low potency, relative to ginkgolide B (GB) at native GlyRs in cultured neurons [180] [181] [182] [183] [184] . In a HEK293 expression system, 1 GlyR, 2 GlyR and 1 GlyR sensitivities to GA inhibition were low compared to the sensitivity of the 2 GlyR [182] .
A high sensitivity to GB inhibition was observed in cultured adult hippocampal neurons and embryonic rat cortical neurons [180] [181] [182] [183] [184] . Furthermore, GB is more active in hippocampal neurons of P14 rats than in hippocampal neurons of P7 rats [185] . From these results it was suggested that heteromers are particularly sensitive to inhibition by GB. Subsequently, coexpression of subunit was directly demonstrated to confer high affinity for GB in a Xenopus oocyte expression study [183] . The GB sensitivity of 2 GlyRs increased 25-fold upon incorporation of the subunit, although a more modest increase (3 -4 fold) was observed for 1 and 3 . A similar increase in sensitivity was observed in 1 (relative to 1) and in 2 (relative to 2) in a HEK293 expression system [182] . In addition, the 1 homomer was observed to be significantly more sensitive than the 2 homomer to GB inhibition in Xenopus oocyte-expressed GlyRs [183] but not in HEK293 cellexpressed GlyRs [182] . Given its sensitivity for subunitcontaining GlyRs, GB has potential as a pharmacological tool to isolate extrasynaptic currents from synaptic currents.
Ginkgolide C (GC) was observed to be the most potent ginkgolide overall, and substitution of any of the hydroxyl groups led to a loss of activity [186] . A high sensitivity to GC inhibition was observed in cultured adult hippocampal neurons and embryonic rat cortical neurons [180] [181] [182] [183] [184] . As with GB, an increase in sensitivity to GC in 1 (relative to 1) and in 2 (relative to 2) was observed [182] . The sensitivities of 1 and 2 homomeric GlyRs to GC inhibition were similar.
Although bilobalide (BB) discriminates weakly among subunits, a drastic reduction in BB sensitivity occurs upon incorporation of the subunit [182] .
Accumulated evidence from combined mutational analysis and electrophysiology (and molecular modelling) indicates that, like the structurally related PTX, ginkgolides bind in the 2'-6' region of the M2 domain [182] [183] . The 1 GlyR T6'F mutation was demonstrated to abolish inhibition by all ginkgolides [182] . Since a phenylalanine residue occupies the 6' position in the subunit, this result appears to be inconsistent with the notion that the subunit can contribute to high affinity GB and GC binding. Furthermore, while 1 and 2 receptors possess identical residues at the 6' level, the two receptors show significantly different ginkgolide sensitivities. It is concluded that, although subunit T6' residue contacts may stabilize receptor -ligand interactions, 2' residues are the most important determinants of ginkgolide binding [182] [183] . Indeed, the increased GA sensitivity of 2 over 1 is mediated by a G2'A substitution [182] . Furthermore, the G2'A mutation to the 1 subunit reduced GB sensitivity to the level seen in 3 subunit, which has an endogenous alanine at the 2' position [183] . The 1 subunit G2'P mutation caused a specific reduction in sensitivity of this receptor to GA and GB inhibition [182] . On the basis of mutant cycle analyses of the interaction between various ginkgolides and 2' mutations, P2' residues and the R2 hydroxyl of GC are proposed to specifically interact [182] . An improved understanding of the molecular mechanisms of these interactions may be forthcoming following an analysis of the subunit sensitivity of ginkgolide J.
-carbolines -Carbolines are best known as inverse agonists at the benzodiazepine site on the GABA A R. The -carbolines, methyl-6,7-dimethoxy-4-ethyl--carboline-3-carboxylate (DMCM), n-butyl--carboline-3-carboxylate ( CCB) and n-methyl--carboline-3-carboxamide (FG7142) inhibit glycine-induced currents in cultured spinal neurons with IC 50 values of 16, 12 and 46 μM, respectively [187] [188] . The sensitivity to CCB decreased with time in culture, and is also decreased in 2 heteromeric GlyRs relative to 2 homomeric GlyRs [188] . These compounds may thus be useful as subunit-specific GlyR antagonists. 5,7-Dichlorokynurenic Acid 5,7-Dichlorokynurenic acid (DCKA) is a potent blocker of the glycine site on the NMDA receptor cation channel. It also inhibits recombinant 2 homomeric GlyRs with an IC 50 near 200 μM [189] . The homomeric 1 GlyR, on the other hand, is completely insensitive to inhibition by this compound. The sensitivity of 1 GlyRs to DCKA is increased by the R196G mutation, which substitutes an 2 residue for an 1 residue near the loop C binding domain [189] . Together with functional data, this result suggests DCKA may be a classic competitive antagonist with a preference for 2-containing GlyRs.
Other Antagonists
A host of other compounds has been shown to either inhibit GlyR currents or antagonise [ 3 H]strychnine binding to the GlyR. Some of these compounds, particularly those derived from GAB-A A R ligands, have potencies in the low micromolar range and may be worthy of further investigation as subunit-specific antagonists and molecular probes of GlyR structure and function. Readers are referred to earlier reviews for coverage of those GlyR antagonists for which no recent information has emerged .
HIGH THROUGHPUT SCREENING
Several high throughput automated techniques have been developed to expedite the discovery and selectivity of novel compounds effective at Cl --selective channels [192] . By virtue of its sensitivity, reproducibility and temporal resolution, patch clamp electrophysiology is considered the gold standard for the characterisation of compounds on ion channels. Although automated patch clamp technology is advancing rapidly, its applicability to high throughput screening currently remains limited by its high expense and limited throughput. Irrespective of this, conventional patch clamp techniques are unlikely to be surpassed soon as a means of quantitating the effectiveness of compounds identified in other assays.
Fluorescence-based assays would appear to have the most potential for high throughput, with the two most important such assays being voltage-sensitive dyes (VSDs) and an anion-quenched yellow fluorescent protein (YFP) [192] . VSD and YFP assays have been applied to the GlyR by Jensen [193] and Kruger [194] , respectively. These assays have comparable dynamic ranges and signal to noise ratios. However, each assay has particular advantages and disadvantages that may prove to be limiting under certain circumstances. The YFP assay is faster by a factor of at least 3 in achieving a given percentage fluorescence change. This time difference could be important if wells must be monitored sequentially but not if the available equipment can monitor multiple wells simultaneously. The VSD assay also consumes dyes, which are expensive, whereas the recurrent costs for the YFP assay should add up to no more than the occasional cDNA plasmid preparation. However, the YFP assay incurs the additional process step of transfection and the additional expense of transfection reagents. Perhaps most importantly, the choice of screening strategy depends on the assay type. Because VSDs label all cells regardless of whether or not they express the channel of interest, they are best suited to homogeneous assays (such as stably expressing cell lines) where all cells are likely to respond to the channel activation stimulus. On the other hand, the YFP assay is also suited to screening heterogeneous assays (i.e., those comprised of multiple cell types) or assays where the transfection rate is significantly < 100 % [194] .
CONCLUSION
The GlyR has emerged as a potential new target for therapeutic agents directed at treating peripheral inflammatory pain, muscle relaxation and movement disorders such as spasticity. To be therapeutically useful for these disorders, drugs need to be able to increase the rate of Cl -flux through glycine-activated channels. This review has considered the molecular pharmacology of a number of compounds that can fulfill this requirement. Of all the potentiating molecules identified to date, it appears that 5HT 3 R antagonists such as tropisetron offer the most promise as therapeutic lead compounds. Tropisetron strongly potentiates recombinant and native GlyRs at nanomolar concentrations, it has excellent oral bioavailability in the central nervous system and it exhibits nociceptive efficacy. A significant problem, however, is that existing tropisetron analogues are not specific for the GlyR. Indeed, a lack of specificity is a common characteristic of virtually all known GlyR potentiating compounds. However, it may not necessarily be an insurmountable problem to identify novel GlyR-specific modulators. As discussed above, tropisetron analogues exhibit drastically different sensitivities and have different modes of action of at the 5HT 3 R and GlyR, implying that their respective binding sites are not identical. This in turn implies that it might be possible to identify GlyR-specific tropisetron analogues. As more is understood about the structural basis of ligand-receptor interactions at the GlyR, the potential for the rational design of novel, GlyR-specific therapeutics will be increased.
Finally, it is important to note that almost nothing is known about the pharmacological properties of 3-containing GlyRs. Because 3 subunits are targets for prostaglandin modulation in spinal nociceptive neurons, antinociceptive drugs targeting the GlyR should ideally be specific for this subtype. A detailed characterization of the pharmacological differences between 3 and 1 subunitcontaining GlyRs is overdue, and is a prerequisite for developing therapeutics specifically targeting particular GlyR subtypes.
ABBREVIATIONS
AChBP
= Acetylcholine binding protein EC = Extracellular EC 50 = Equivalent agonist concentration required to activate 50% of maximum available current EMTBL = -Ethyl -methyl--thiobutyrolactone GABA = -Aminobutyric acid GABA A R = -Aminobutyric acid type-A receptor GABA C R = -Aminobutyric acid type-C receptor GlyR = Glycine receptor 5HT 3 R = 5-Hydroxytryptamine type-3 receptor IC 50 = Equivalent antagonist concentration required to inhibit 50% of activated current cys-loop = Cysteine loop MTS = Methanethiosulfonate MTSEA = MTS Ethylammonium nAChR = Nicotinic acetylcholine receptor PGE 2 = Prostaglandin 
